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a b s t r a c t 
Myocardial fibrosis is the excessive deposition of extracellular matrix proteins, including collagens, in the 
heart. In cardiomyopathies, the formation of interstitial fibrosis and/or replacement fibrosis is almost al- 
ways part of the pathological cardiac remodeling process. Different forms of cardiomyopathies show par- 
ticular patterns of myocardial fibrosis that can be considered as distinctive hallmarks. Although formation 
of fibrosis is initially aimed to be a reparative mechanism, in the long term, on-going and excessive my- 
ocardial fibrosis may lead to arrhythmias and stiffening of the heart wall and subsequently to diastolic 
dysfunction. Ultimately, adverse remodeling with progressive myocardial fibrosis can lead to heart fail- 
ure. Not surprisingly, the presence of fibrosis in cardiomyopathies, even when subtle, has consistently 
been associated with complications and adverse outcomes. In the last decade, non-invasive in vivo tech- 
niques for visualization of myocardial fibrosis have emerged, and have been increasingly used in research 
and in the clinic. In this review, we will describe the epidemiology, distribution, and role of myocardial fi- 
brosis in genetic cardiomyopathies, including hypertrophic, dilated, arrhythmogenic, and non-compaction 
cardiomyopathy, and a few specific forms of genetic cardiomyopathies. 
© 2019 The Author(s). Published by Elsevier Inc. 






































Heart failure (HF) is a major cause of morbidity and mortal-
ty worldwide and is expected to increase in the next years due
o the aging population [1] . HF is defined by an inadequate cir-
ulation, due to loss of cardiac pump function, and consequently
he inability to provide other tissues with an adequate amount
f blood and oxygen [1] . Cardiomyopathies are a group of struc-
ural and functional disorders that affect the heart muscle and
ften lead to HF [2] . A diagnosis of cardiomyopathy implies that
o underlying pathophysiology such as (untreated) coronary artery
isease, hypertension, valvular disease or congenital heart de-
ect can explain the myocardial remodeling and abnormalities [2] .✩ Declaration of Competing Interest: The UMCG, which employs the authors, has 
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050-1738/© 2019 The Author(s). Published by Elsevier Inc. This is an open access articleardiomyopathies are categorized based on morphological and
athological characteristics of the heart [2] . The most common
ypes of genetic cardiomyopathies include hypertrophic, dilated, ar-
hythmogenic, restrictive, and non-compaction cardiomyopathy [2] .
n genetic cardiomyopathies, generally changes occur in the struc-
ure and function of cardiomyocytes, and this is often associated
ith formation of fibrosis. Indeed, a hallmark of cardiomyopathies
nd HF is cardiac fibrosis. In this review, we will discuss the epi-
emiology, distribution, and role of myocardial fibrosis in hyper-
rophic, dilated, arrhythmogenic, and non-compaction cardiomy- 
pathy, and forms of cardiomyopathy with a unique pattern of
yocardial fibrosis. 
yocardial fibrosis 
In the healthy heart, the cardiomyocytes are tightly arranged
nd coupled for synchronization of electrical conduction and con-
raction. The architecture of the cardiac muscle is heavily defined
y a network of extracellular matrix (ECM) proteins, a non-cellular
etwork that functions as a scaffold, and contains numerous cells,
ncluding cardiac fibroblasts (CFs) [3] . The main component of the
ardiac ECM is collagen, consisting of approximately 85% type I col-
agen, which is important for strength, and 11% type III collagen,
hich is important for elasticity [3] . The ECM has a high turnover
f proteins, mainly mediated by the CFs [4] . CFs synthesize theunder the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
354 T.R. Eijgenraam, H.H.W. Silljé and R.A. de Boer / Trends in Cardiovascular Medicine 30 (2020) 353–361 
Fig. 1. Myocardial fibrosis can be present as replacement/scarring, reactive interstitial, and perivascular fibrosis, or as a combination. The different cell types that are involved 
are shown in the panels on the left: fibroblasts (green), inflammatory cells (blue), and cardiomyocytes (red), with fibrillar debris interpositioned. (From: de Boer RA et al. 


















































p  ECM proteins, including collagen, while matrix metalloproteinases
(MMPs) break down ECM proteins. MMPs are, in turn, regulated by
tissue inhibitors of metalloproteinases (TIMPs) [4] . Indeed, the ECM
is not static, but rather a very dynamic structure, with continuous
synthesis and degradation at all times. 
Fibrosis is a characteristic of many chronic diseases, including
cardiac disease and HF. In case of myocardial fibrosis, the bal-
ance between synthesis and degradation of ECM proteins is dis-
turbed, leading to excess fibrous connective tissue formation [3] . A
main event that occurs is CF activation and differentiation into my-
ofibroblasts, which is primarily triggered by transforming growth
factor (TGF-) β [5] . Myofibroblasts secrete higher amounts of ECM
proteins, thereby playing a key role in fibrosis formation [4] . Based
on the cause and appearance, fibrosis can be divided into differ-
ent subtypes: reactive interstitial fibrosis, infiltrative perivascular
fibrosis, and replacement fibrosis ( Fig. 1 ) [6] . Interstitial fibrosis is
characterized by an increase in ECM and collagen deposits between
the cells without loss of cardiomyocytes. The fibrosis is diffusely
present throughout the myocardium. This type of fibrosis is mostly
caused by chronic triggers, such as pressure overload (hyperten-
sion), inflammation, and aging [6] . Perivascular fibrosis is charac-
terized by accumulation of collagen fibres in the area surrounding
the coronary arteries, and is mainly observed in the setting of hy-
pertension [6] . Replacement fibrosis presents following cardiomy-
ocyte death, and occurs for instance after acute ischemic injury,
such as myocardial infarction (MI) ( Fig. 2 ) [6] . In multifactorial forms of HF, generally in older patients or in
atients with hypertension, diabetes mellitus (DM), and coronary
rtery disease (CAD) with MI, the triggers for cardiac remodeling
nd fibrosis are well known. For instance, chronic pressure over-
oad, such as hypertension and valvular disease, causes activation
f TGF- β with a subsequent process of interstitial fibrosis [7] . MI
s characterized by substantial cell loss, which necessitates repar-
tive fibrosis [8] . However, the triggers in cardiomyopathies are
ess well studied, and thus less clear. In hypertrophic cardiomyopa-
hy, we know that the cellular changes and growth at the sites of
ypertrophy are uncontrolled, with a typical pattern disarray and
ell loss, and patchy replacement fibrosis can be discerned [9] . On
he other hand, in dilated cardiomyopathy, stretch of the ventricle
ue to dilatation causes cardiac remodeling, paracrine signaling of
he cardiomyocytes to the CFs, and activation of pro-fibrotic neuro-
ormonal systems, most notably the renin-angiotensin-aldosterone
ystem, with myocardial interstitial fibrosis as a result [10] . Other
orms of cardiomyopathies are characterized by other triggers, but
he exact culprits and sequelae of events are unknown. 
As cardiomyocytes have negligible regenerative capacity, severe
ardiomyocyte loss cannot be compensated by the generation of
ew cardiomyocytes. The subsequent loss of tissue will therefore
ave to be repaired by generation of fibrotic scar tissue [3] . In oth-
rs words, initially, fibrosis formation often is a reparative reac-
ion to maintain cardiac structural integrity and strength, and may
revent dramatic events such as cardiac rupture. The presence of
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Fig. 2. Overview of the different types of cardiomyopathies that were discussed in this review and their distinct types and patterns of myocardial fibrosis. Healthy my- 
ocardium is visualized as dark areas without fibrosis, while fibrotic patches are observed as bright areas of LGE. (CMR images from: Posch et al. Heart Rhythm 2009;6(4):480–
486 [66] , Doltra et al. Biomed Res Int 2013;2013:676,489 [81] , Ismail et al. Heart 2014;100(23):1851–1858 [82] , Lehrke et al. Heart 2011;97(9):727–732 [38] , Waterhouse et al. 





















v  brosis has consistently been associated with worse clinical out-
omes. Clearly, this will be confounded by the fact that most se-
ere cardiomyopathy will be accompanied by the most extensive
brosis. However, the sheer presence of fibrosis, especially when
isproportionate to the severity of the disease, may cause specific
linical presentation that is disadvantageous. For instance, myocar-
ial tissue becomes stiff and less compliant when excessive fibro-
is forms, resulting in diastolic dysfunction [11] . Further, intersti-
ial or patchy fibrosis is accompanied with electrical events that
ay cause arrhythmias, such as re-entry circuits and areas of au-
omated automaticity [12] . isualization of myocardial fibrosis 
The gold standard for the investigation of myocardial fibrosis
onsists of histological analysis of endocardial biopsies (EMB), for
xample using Masson’s trichrome or Sirius red staining [6] . How-
ver, since the collection of tissue samples requires an invasive
rocedure, and explanted tissues are not commonly available for
cientific purposes, the data from histological studies are scarce.
urthermore, obtaining EMB is subject to sampling error, as it usu-
lly is taken via right-sided heart catheterization from the right
entricular (RV) septal area. In other words, absence of fibrosis in































































































































L  EMB does not at all rule out the presence of (extensive, patchy)
fibrosis elsewhere in the heart. Alternatively, non-invasive tech-
niques have emerged to investigate cardiac fibrosis in vivo , most
commonly using cardiac magnetic resonance (CMR) imaging. An
example is the use of late gadolinium enhancement (LGE) [13] .
Gadolinium (Gd) is a chemical element that creates a visible con-
trast on CMR. By intravenously injecting a bolus of Gd, bound
to a carrier molecule that is relatively large and therefore cannot
pass the cell membrane, the Gd will rapidly diffuse out of the
blood vessels into the tissues, including the heart. In the heart,
it cannot invade into intact cardiomyocytes, and will therefore
distribute across the extracellular space. Passively accumulated Gd
will slowly diffuse out of the tissue and is eventually cleared by
the kidneys. In case of damaged cells or fibrosis, there is more ex-
tracellular space and therefore a greater amount of Gd, resulting
in a delayed wash in and wash out, which can be visualized on
CMR [13] . Normal myocardium is visualized as a “dark” area with-
out Gd, and damaged myocardium will be seen as “bright” areas of
Gd accumulation. The extent of LGE can be quantified and the ac-
curacy of LGE-CMR to visualize focal myocardial fibrosis has been
validated by a close correlation to histologically proven cardiac fi-
brosis [14] . 
The major disadvantage of LGE is its limited resolution in the
detection of myocardial fibrosis. LGE is an all-or-nothing approach,
which is very sensitive to regional Gd accumulation, and is there-
fore able to visualize focal regions of (replacement) fibrosis but not
diffuse interstitial fibrosis [13] . In order to overcome this limita-
tion, new CMR techniques using T1 mapping have been developed.
T1 mapping consists of the generation of a pixelated map based on
the longitudinal or spin-lattice relaxation of protons that recover
towards thermodynamic equilibrium following excitation with the
radiofrequency beam [15] . The value of T1 relaxation time varies
according to the state of the molecular environment. The native T1
value is a tissue-specific time constant in the absence of an ex-
ogenous contrast agent. Tissues generally contain water but patho-
logical processes, including fibrosis, alter the water composition
and thereby alter the T1 values. In case of myocardial fibrosis, an
increase in native T1 relaxation time will be observed. T1 map-
ping can also be combined with administration of Gd, which in-
creases proton relaxation, and thus decreases T1 relaxation time
[15] . Therefore, in contrast to the native T1 relaxation time, in case
of myocardial fibrosis, the post-contrast T1 values will be lower.
Native and post-contrast T1 mapping can determine an increase in
ECM volume that is not detectable by LGE. 
Fibrosis in hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) is characterized by left
ventricular hypertrophy (LVH), which cannot be explained by ab-
normal loading conditions (e.g. hypertension) [16] . In the early
stages, HCM can present with a non-dilated left ventricle (LV), and
a normal LV ejection fraction (EF) or even hypercontractility [16] .
In the late phase of the disease, often a dilated LV and diastolic
dysfunction are observed [16] . Most commonly, the hypertrophy is
asymmetrical and is predominantly located in the interventricu-
lar septal (IVS) wall at the basal level, but hypertrophy may also
present apical or elsewhere in the heart [16] . Diagnosis of HCM is
based on the presence of a diastolic LV wall greater than 15 mm
during cardiac imaging [16] . However, in children a Z-score is used
to reflect deviation from an age- and sex-matched population [16] .
Myocardial fibrosis has been extensively researched in HCM. In
a study by Galati et al. [17] , 30 hearts that were explanted from
end-stage HCM patients due to severe HF were histologically ana-
lyzed to quantitatively determine the extent, type and distribution
of myocardial fibrosis. All hearts had massive amounts of myocar-
dial fibrosis, ranging from 23% to 56%, with an average amount of7% [17] . The type of myocardial fibrosis was determined and clas-
ified as interstitial or replacement fibrosis, or as a combination
17] . The most prominent type of myocardial fibrosis was replace-
ent fibrosis, which was present in more than half of the cases,
ollowed by a combination of replacement and interstitial fibro-
is in a third of the cases [17] . Interstitial fibrosis alone was only
een in one in ten cases [17] . The distribution of myocardial fibrosis
as assessed along the three axes, longitudinal (base-to-apex), cir-
umferential (anterior, posterior, lateral and septal), and transmu-
al (epicardial-to-endocardial) [17] . Along the longitudinal axis, the
mount of fibrosis was progressively increasing when going from
ase to apex [17] . Considering the circumferential axis, the LV free
all and the IVS, especially at the LV and RV insertion points, were
ostly affected [17] . In contrast, the posterolateral LV wall and RV
ere least involved [17] . Finally, the epicardial-to-endocardial dis-
ribution showed that myocardial fibrosis was mostly present in
he mid-ventricular layer [17] . 
Since the tissues that are available for histological evaluation
f myocardial fibrosis are usually derived from end-stage disease,
hen the amount of fibrosis may have accumulated to extreme
mounts, these studies do not provide insight in the development
f myocardial fibrosis during disease progression. For this reason
nd the fact that explanted tissues are scarce, most studies use
GE-CMR. These studies have reported that the majority (42% to
2%) of HCM patients have LGE on CMR, indicating the presence of
ense focal scarring [18–23] . Similar to the above mentioned his-
ological findings, the reported amount of myocardial fibrosis was
xtensive as the extent of LGE went up to 65% of total LV mass, and
as mostly present at the IVS and the insertion points of the RV to
he LV. Interestingly, the presence and extent of LGE were of great
rognostic value since they have been associated with several ad-
erse clinical outcomes, including contractile dysfunction [20 , 23] ,
ardiac arrhythmias [18–20] , and cardiovascular and all-cause mor-
ality [19–22] . Since LGE is only capable of visualizing dense scar
issue, newer studies have used T1-weighted imaging [24–27] .
on-contrast, native T1 relaxation times were increased in HCM
atients, indicating the presence of interstitial fibrosis [24–26] .
1 values were higher in segments with LGE than in segments
ithout LGE but were also higher than normal in regions without
GE, meaning that, besides patches of fibrosis, also diffuse intersti-
ial fibrosis was present that was not detected by LGE [24] . Simi-
arly, presence of interstitial fibrosis was demonstrated by shorter
ost-contrast T1 relaxation times in HCM patients after adminis-
ration of Gd [25 , 27] . In line with the findings using LGE, it has
een reported that the myocardial T1 times correlated with dias-
olic function [27] . Together, these studies show that both diffuse
nterstitial fibrosis and dense focal replacement fibrosis are com-
only present in HCM patients and can be visualized by CMR. 
In addition to the use of imaging techniques to visualize my-
cardial fibrosis, a few studies have investigated the utility of
erum biomarkers in the assessment of cardiac remodeling in
CM. High sensitivity cardiac troponin T (hs-cTnT) is a marker of
ardiomyocyte death as troponin is released from permeabilized,
ead cardiomyocytes. Indirectly, hs-cTnT could indicate myocardial
brosis as cardiomyocyte loss is replaced by fibrosis [28 , 29] . It
as been reported that hs-cTnT serum levels are higher in HCM
atients compared to healthy controls, and that increasing lev-
ls of hs-cTnT are associated with increasing amounts of myocar-
ial fibrosis [28 , 30] . A study by Roncarati et al. [31] demonstrated
hat circulating miRNA-29a, which is produced by fibroblasts, and
lays a role in fibrosis by regulating collagen gene expression,
as positively correlated with myocardial fibrosis in HCM patients.
lso, plasma levels of MMP-9 have been shown to be increased
n HCM patients [32] . Interesting results have been found in pa-
ients that carry a pathogenic sarcomere mutation but do not have
VH. These genotype positive-phenotype negative ( G + P -) patients































































































































b  ere also shown to have myocardial fibrosis, evidenced by pres-
nce of LGE and increased T1 relaxation times [33 , 34] . In addition,
o et al. [23] demonstrated that serum levels of procollagen I C-
erminal propeptide (PICP), a marker of collagen synthesis, were
levated in G + P - HCM patients, and even higher in patients with
n established phenotype. Moreover, the ratio of PICP to collagen
ype I C-terminal telopeptide (CITP), which reflects the balance be-
ween collagen synthesis and degradation, was unchanged in phe-
otype negative patients but was higher in patients with overt
CM, suggesting that at first collagen synthesis and degradation
re balanced but later collagen synthesis exceeds degradation [23] .
ogether, these findings suggest that myocardial fibrosis may be an
arly disease manifestation, independent of LVH and other abnor-
alities. 
In summary, in the majority of HCM patients, often extensive
mounts of fibrosis are observed. Typical to HCM, this is most
ommonly seen as patchy replacement fibrosis, either alone or in
ombination with interstitial fibrosis, and mostly present at the
basal) IVS and the attachment of the RV and LV ( Fig. 2 ). This can
e assessed using LGE and T1 mapping on CMR, but also serum
iomarkers have been shown to be useful. The presence and extent
f fibrosis have consequences for disease penetration and progno-
is. 
ibrosis in dilated cardiomyopathy 
On the opposite site of the spectrum of cardiomyopathies is di-
ated cardiomyopathy (DCM), which is characterized by ventricular
ilatation and often progressive contractile dysfunction, resulting
n great risk of developing HF [10] . Diagnosis of DCM is based on
 LVEF below 45% and an end-diastolic LV diameter greater than
17% during cardiac imaging in the absence of other known causes
f myocardial disease [10] . 
Several studies using LGE-CMR have reported that one third to
wo thirds (30–66%) of DCM patients have focal myocardial fibro-
is [35–38] . Although less extensive than in HCM patients, gen-
rally substantial myocardial fibrosis can be determined, up to
6% of total LV mass. LGE distribution is typically indicated as
idwall fibrosis, which sets it apart from LGE distribution ob-
erved in ischemic heart disease [35–37] . DCM patients with mid-
all fibrosis have been reported to have greater LV dilatation and
orse LVEF than DCM patients without midwall fibrosis [36 , 38] .
urthermore, the presence and extent of LGE have been associ-
ted with adverse clinical outcomes, including cardiac arrhythmias,
F severity, higher rates of cardiac transplantation, implantable
ardioverter/defibrillator (ICD) implantation and cardiac resynchro-
ization therapy (CRT), and cardiovascular and all-cause mortal-
ty [36–38] . Presence of interstitial fibrosis was also observed,
videnced by increased mean native T1 relaxation times and de-
reased post-contrast T1 relaxation times in DCM patients, even in
he absence of LGE [24 , 25] . 
A unique study, performed by Gulati et al. [36] , had explanted
earts of 16 DCM patients after heart transplantation or death for
istological assessment of myocardial fibrosis together with CMR
ata. Staining of the explanted hearts validated the findings on
MR studies performed in the same patients prior to their death or
ransplant, confirming presence of extensive midwall replacement
brosis in DCM patients [36] . 
Two studies reported that serum levels of several fibrosis mark-
rs, including procollagen type III (PCIII), connective tissue growth
actor (CTGF), MMP-2, MMP-9 and TIMP-1, were increased in DCM
atients compared to healthy controls [39 , 40] . Interestingly, only
CIII was even higher in DCM patients with detectable fibrosis than
n DCM patients without detectable fibrosis [39] . 
To summarize, many DCM patients present with substantial
mounts of myocardial fibrosis. In these patients, myocardial fi-rosis is mostly observed as replacement fibrosis with a midwall
istribution throughout the LV ( Fig. 2 ). Similar to HCM, myocardial
brosis is related to disease severity in DCM. 
ibrosis in arrhythmogenic cardiomyopathy 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an
nherited form of heart disease and is characterized by ventricu-
ar arrhythmias (VAs) and contractile dysfunction with a high risk
or sudden cardiac death (SCD), particularly in young patients and
thletes [41] . Initially, this type of cardiomyopathy was thought to
redominantly affect the right side of the heart but nowadays it is
ncreasingly recognized to involve both ventricles, resulting in the
roader term of arrhythmogenic cardiomyopathy (ACM) [41] . The
allmark characteristic of ARVC is the replacement of myocardial
issue, mainly of the RV, by fibrofatty tissue [41] . In addition, de-
eneration of the myocardium and fibrosis are present [41] . There
s no gold standard in the diagnosis of ARVC [41] . Instead, diag-
osis is based on a scoring system comprised of multiple aspects
uch as genetic factors, electrocardiographic and histological abnor-
alities, arrhythmias, and structural or functional alterations, di-
ided into major and minor criteria based on their association with
RVC [41] . Diagnosis of ARVC is fulfilled when 2 major criteria, 1
ajor plus 2 minor, or 4 minor criteria from different categories
re present [41] . 
Since the key hallmark of ARVC is cardiac fibrofatty replace-
ent, the use of LGE is not included in the current Task Force
riteria for diagnosis of ARVC [42] . Only a few studies have in-
estigated LGE on CMR in ARVC [43–46] . These studies reported
he presence of RV LGE in 39% −88% of ARVC patients. The high
ariability between studies might be explained by the low num-
er of patients ( n = 8–23) that were studied. LGE was most com-
only found in the RV outflow tract, RV free wall and RV wall of
he IVS ( Fig. 2 ). Regions of LGE were described to show motion
bnormalities [43 , 44] . In two studies EMBs or explanted heart tis-
ues were available from a small number of patients and histo-
ogical examination confirmed the presence of extensive myocar-
ial fibrosis in the RV wall [43 , 44] . In a study by Tandri et al.,
43] presence of LGE predicted inducibility of ventricular tachycar-
ia (VT) during electrophysiological testing. Moreover, there was a
trong association between the extent of LGE and RV dysfunction
43 , 45] . In addition to RV LGE, two studies reported presence of
GE in the LV in 50% and 33% of ARVC patients, consistent with
he increasingly recognized paradigm that ARVC has biventricular
nvolvement [44 , 46] . 
There are several limitations that complicate the use of LGE
n ARVC. One limitation is the thin RV wall and the pronounced
hinning of the RV wall in ARVC [42] . In addition, it is challeng-
ng to distinguish myocardial fibrosis from fibrofatty replacement
y LGE sequences, introducing great interobserver variability [42] .
hree-dimensional (3D) electroanatomic voltage mapping (EVM) is
 technique to accurately characterize presence, localization, and
xtent of so-called low-voltage areas (LVAs) or “electroanatomi-
al scars” [47] . LVAs have been proven to correspond with RV ar-
as of pathological myocardial substrates [47] . Indeed, increasing
mounts of RV LGE were associated with the extent of LVAs but
VM has been shown to provide a more accurate measurement of
ffected myocardium in ARVC patients, evidenced by presence of
VAs in 64–91% of patients [45 , 46 , 48] . However, the main disad-
antage of EVM is that it is an invasive procedure as it requires car-
iac catheterization, whereas LGE can be used noninvasively [45] . 
In summary, even though ARVC is mainly characterized by fi-
rofatty replacement, and determination of myocardial fibrosis in
ivo could be challenging, the presence of focal RV myocardial fi-
rosis is related to the severity of RV dysfunction and the presence
























































































































p  of VT. Additionally, myocardial fibrosis is not limited to the right
side of the heart but may also be observed in the LV. 
Fibrosis in non-compaction cardiomyopathy 
Left ventricular non-compaction (LVNC) is a very rare form
of cardiomyopathy, which is characterized by structural abnor-
mality of the LV myocardium [49] . The etiology of LVNC is un-
known but is believed to be genetic in nature, causing failure of
the compaction process of the myocardial wall during develop-
ment [49] . The key hallmark of LVNC is the two-layered structure
of the LV myocardium at the apical and lateral sides, consisting
of a spongy (non-compacted), trabeculated endocardial layer and
a thinner compacted epicardial layer [49] . The ratio of non-
compacted to compacted myocardium is the main criterion for di-
agnosis of LVNC, and is met when the ratio is greater than 2:1 at
end-systole using echocardiography or 2.3:1 at end-diastole using
CMR [49] . 
A limited amount of studies have investigated myocardial fi-
brosis in small numbers ( n = 13–47) of LVNC patients [50–56] .
These studies reported the presence of LGE on CMR in 33% −74%
of LVNC patients. The average reported amount of LGE was rel-
atively small when compared to the cardiomyopathies that were
previously discussed, ranging from 5% to 8% of total LV mass.
LGE was present in both compacted and non-compacted myocar-
dial segments but most commonly in the compacted region, and
mainly in the IVS [50–53] . LGE was most frequently seen as mid-
myocardial [51–54] . Even though the amount of myocardial fibro-
sis is low, LVNC patients with LGE were demonstrated to have
greater LV volume than patients without LGE, and presence and
extent of LGE were independently related to LV systolic function
[51 , 53–55] . Moreover, LVNC patients with LGE had a higher risk of
developing arrhythmias [53 , 55] . Mean native T1 relaxation times
of the compacted myocardium of LVNC patients were higher than
healthy control myocardium [54 , 56] . Furthermore, LGE-positive pa-
tients had higher native T1 values than patients without LGE, and
native T1 values showed an inversed correlation with LVEF [54 , 56] .
Nucifora et al. [51] observed presence of LGE in approximately 20%
of asymptomatic LVNC patients and LVNC patients with preserved
systolic function, which suggests that myocardial fibrosis may be
an early disease manifestation. 
The study of Szemraj-Rogucka et al. [53] determined the plasma
levels of four miRNAs, which are well established in myocardial fi-
brosis, miRNA-21, miRNA-29a, miRNA-30d and miRNA-133a. They
demonstrate that plasma levels of all 4 miRNAs are elevated in
LVNC patients as compared to healthy controls. In addition, plasma
levels were higher in LVNC patients with LGE as compared to LVNC
patients without LGE. The only study in which an EMB sample was
available was a case report by Kalavakunta et al., [57] in which his-
tological examination showed a vast amount of replacement fibro-
sis, similar to the findings with CMR. 
To summarize, myocardial fibrosis was mostly present in the
compacted myocardium, and most commonly in the IVS ( Fig. 2 ).
The presence of patches of myocardial replacement fibrosis, al-
though to a lesser extent than in other forms of cardiomyopathy,
correlated with the severity of systolic dysfunction and the risk of
arrhythmias in LVNC. Moreover, in these patients, the serum levels
of miRNAs related to fibrosis were indicative of myocardial fibrosis
severity. 
Cardiomyopathies with different disease manifestations and 
divergent patterns of myocardial fibrosis 
The cardiomyopathies described above adhere to common de-
scriptions. There are, however, also additional gene mutations
causing cardiomyopathies that cannot be automatically included inne of these categories, as they exhibit a specific clinical presenta-
ion, often also with divergent fibrotic patterns. 
Laminopathies are caused by pathogenic variants in the lamin
/C ( LMNA ) gene [58] . The lamin A and C proteins are pro-
uced via alternative splicing of this gene, and are components
f the nuclear lamina and hence essential in proper nuclear ar-
hitecture and function. Several autosomal dominant mutations in
he LMNA gene have been associated with cardiac disease that
nally can culminate in a DCM phenotype. This cardiomyopa-
hy is, however, also characterized by early-onset atrioventricular
AV)-block, (supra)ventricular arrhythmias, and SCD even before
CM development [59] . Thus, in contrast to idiopathic DCM, these
aminopathies have a higher occurrence of conduction system de-
ects and VAs. Interestingly, the unusual structural abnormalities
n laminopathies include fibrosis within the IVS, near the region
f the conduction system, as has been revealed by autopsy studies
60] . Several imaging studies using LGE have shown midmyocar-
ial basal and septal fibrosis [61–63] . The basal septal scar also
akes catheter ablation of VAs very challenging and this procedure
s associated with a poor prognosis in this patient population. [64] .
he localized fibrosis in the IVS may be the mechanism behind re-
uced septal function, AV-block, and VA in lamin A/C mutation-
ositive subjects. In conclusion, the fibrotic pattern in laminopathy
atients appears different from other DCM patients and even has
ome HCM (septal fibrosis) characteristics. 
Another form of cardiomyopathy that is present with specific
isease is the phospholamban (PLN) p.Arg14del induced cardiomy-
pathy. Our group has extensively characterized this form of car-
iomyopathy, which interestingly shows a unique pattern of my-
cardial fibrosis that is different than the other cardiomyopathies
hat were discussed previously. PLN is a sarcoplasmic reticulum
SR) membrane protein expressed in cardiomyocytes and involved
n calcium handling by negatively regulating the SR Ca 2 + -ATPase
SERCA) protein [65] . This mutation in the PLN gene, deleting the
rginine on position 14 of the PLN protein, results in a severe form
f cardiomyopathy with characteristics of DCM and ARVC [65] . Mu-
ation carriers have a high risk of developing arrhythmias and end-
tage HF with high mortality and poor prognosis from late adoles-
ence [65] . This mutation has been found in about 14% of Dutch
CM and ARVC patients and is therefore the most identified mu-
ation in cardiomyopathy patients in the Netherlands [65] . 
Two studies have demonstrated the presence of focal myocar-
ial fibrosis in PLN-R14del mutation carriers using LGE on CMR,
hich was mainly observed in the posterolateral LV wall [66 , 67] .
n the study of te Rijdt et al. [67] , it was reported that out of 150
LN-R14del mutation carriers that were enrolled in the PHORE-
AST study who underwent CMR imaging, 50 mutation carriers
9/10 index patients and 41/140 relatives) showed LGE. The median
xtent of LGE was 6% of total LV mass and was higher in index pa-
ients (18%) than their relatives (5%). Almost all mutation carriers
10/11) with impaired LV systolic function had LGE. The RV only
howed LGE in 5% of mutation carriers but these mutation carriers
ad lower RV function compared to mutation carriers without RV-
GE. LGE was also observed in mutation carriers with preserved LV
unction, suggesting that fibrosis is an early mutation-related re-
odeling process that precedes detectable ventricular dysfunction
66 , 67] . Both studies reported an association between the presence
nd localization of LGE and low-voltage ECG, a typical characteris-
ic in PLN-R14del mutation carriers, suggesting that myocardial fi-
rosis is the substrate of these ECG abnormalities [66 , 67] . Finally,
e Rijdt et al. reported that the presence of LGE was independently
ssociated with the occurrence of VA, stressing the clinical impor-
ance of fibrosis in this disease [67] . 
Several studies have performed histological analysis on hearts
f patients with the PLN-R14del mutation after autopsy or trans-
lantation, confirming the findings using LGE on CMR [67–70] .


























































































































imilar to the observed localization of LGE, extensive interstitial
yocardial fibrosis was mostly present in the epicardial layer of
he posterolateral LV wall and to a lesser extent in the septum
nd right ventricle [67–70] . The distribution of myocardial fibrosis
as not different between patients with a predominantly DCM or
RVC phenotype [68] . Additionally, Sepehrkhouy et al. [70] com-
ared the distribution of myocardial fibrosis in PLN-R14del hearts
ith hearts with desmosomal, lamin A/C, sarcomeric and desmin
utations. It was demonstrated that together with desminopathy,
LN-R14del hearts had the highest amount of myocardial fibrosis.
n addition, the epicardial distribution of fibrosis in the postero-
ateral LV wall was found to be a distinct pattern in PLN-R14del
ardiomyopathy ( Fig. 2 ). 
In summary, specific mutations causing cardiomyopathy may
ive rise to myocardial fibrosis patterns that are distinct from most
ther types of cardiomyopathy, as exemplified by laminopathies
nd PLN-R14del cardiomyopathy. These distinct fibrotic patterns
re also associated with specific disease characteristics, and there-
ore the fibrotic pattern recognition has clinical importance. 
an we treat myocardial fibrosis? 
Given the importance of myocardial fibrosis for many different
ypes of cardiomyopathies, attempts have been made to inhibit or
ttenuate fibrosis formation. 
TGF- β is the best-known fibrogenic factor in myocardial fibro-
is formation. TGF- β expression in the heart is increased with car-
iac stress and during myocardial fibrosis, and exerts profibrotic ef-
ects amongst others via fibroblast activation and downregulation
f TIMPs [71] . There are two FDA-approved drugs, pirfenidone and
ranilast, which have an effect on fibrosis by inhibition of the TGF-
signaling pathway. Pirfenidone, initially used for treatment of id-
opathic pulmonary fibrosis, has been reported to reduce fibrosis in
ats with MI [72] . Tranilast, originally used as an antihistamine in
sthma, was found to reduce fibrosis in diabetic rats [73] . However,
nhibition of the TGF- β receptors 1 and 2 (TGF βR1 and TGF βR2)
as been shown to reduce cardiac fibrosis in mouse models but
esulted in increased mortality, suggesting that TGF- β is not only
etrimental but is necessary to maintain a normal ECM [74] . 
The renin-angiotensin-aldosterone system (RAAS) plays a key
ole in homeostasis of blood pressure and tissue perfusion [75] .
hen blood pressure is decreased, a homeostatic feedback mecha-
ism is activated in the kidneys, in which angiotensin (Ang) II pro-
uction is stimulated to restore blood pressure via vasoconstriction
nd fluid retention [75] . AngII and aldosterone can stimulate col-
agen synthesis. Additionally, AngII can reduce MMP-1 activity and
an induce TGF- β1 expression via the angiotensin type-I (AT1) re-
eptor in CFs. Together, these effects contribute to increased my-
cardial fibrosis, and therefore have been proposed as therapeutic
argets. The use of aliskiren, a renin inhibitor, has been shown to
revent myocardial collagen deposition in a mouse model of my-
cardial fibrosis [76] . In addition, angiotensin-converting enzyme
ACE) inhibitors, including captopril, have been reported to reduce
rrhythmias and improve cardiac function [77] . Administration of
alsartan, an AngII receptor blocker (ARB), was also found to re-
uce perivascular fibrosis in a pressure overload mouse model [78] .
imilarly, the AT1 receptor antagonist losartan was shown to sup-
ress myocardial fibrosis in patients with end-stage renal disease
79] . Finally, inhibition of aldosterone using spironolactone pre-
ented the increase in myocardial collagen in rats [80] . 
In conclusion, targeting myocardial fibrosis as a therapeutic
arget in cardiomyopathies seems reasonable, and experimental
ata are promising. However, it needs to be taken into account
hat for normal structure and function, the heart depends on a
ell-balanced ECM, and that shifting the balance towards the
ther extreme may have detrimental effects as well. Indeed, fibro-is formation has several bona fide functions, and interfering with
brogenesis could be detrimental. Clearly, generation of solid ex-
erimental and mechanistic data should precede any clinical trial. 
linical impact 
Currently advocated diagnostic and treatment guidelines do
ot include the recommendation to visualize or target myocardial
brosis. Most guidelines made use of cohorts with long-term
ollow-up, and it has taken 10–20 years to accumulate end-
oints based on which prognostic models can be calculated.
ince echocardiography has been the imaging tool of choice for a
ong term, HCM and DCM still largely rely on echocardiography.
owever, in the near future, we foresee that existing databases
ill be enriched with data from CMR and thus with parameters of
yocardial fibrosis. These parameters will be evaluated for their
ncremental prognostic impact – existing analyses from (small) co-
orts suggest that LGE or T1 relaxation time may have incremental
alue in this respect. Clearly, this might change current algorithms
ith regards to timing of start of pharmacological therapies or
mplantation of ICDs. Clearly, performing LGE-CMR is more time-
onsuming and costly, and not every hospital has the required MRI
quipment or techniques at their disposal, so proposed algorithms
hould also consider limited resources and identify patients in
he gray zone whose management is most likely to change and
ustify using additional, more expensive techniques. Arguably, a
ro-fibrotic phenotype might prompt a physician for fast referral
or ICD or aggressive pharmacotherapy. On the other hand, in the
bsence of fibrosis, a strategy of watchful waiting may be justified
s we know that short and middle term prognosis are good. 
oncluding remarks 
Detection of myocardial fibrosis in vivo using LGE or T1 map-
ing has been shown to be highly accurate, and to have great prog-
ostic value in the types of cardiomyopathies that we have dis-
ussed in this review. Presence and extent of myocardial fibrosis
ave been associated with several adverse clinical outcomes. In ad-
ition, the different forms of cardiomyopathies that were discussed
xert distinct types and patterns of myocardial fibrosis (summa-
ized in Fig. 2 ), which may be useful in the identification of the
isease. Moreover, there are several indications that myocardial fi-
rosis could be an early manifestation of cardiomyopathy, suggest-
ng that early recognition could help in the determination of a
herapeutic strategy. 
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